Modig Berndt sold $71K of PHVS

Modig Berndt (Chief Executive Officer) sold 2,291 shares of Pharvaris N.V. (PHVS) at an average of $31.07 ($31.05–$31.46) across 2 trades on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Modig Berndt
Published Jun 17, 2026, 9:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
high confidence
Mentioned
$PHVS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The newest disclosed fact is the CEO’s open-market sale of 2,291 shares on 2026-06-15 at ~$31.07 average, under a pre-arranged 10b5-1 plan.

02

Market read

This is a routine insider-sale filing; it may marginally affect sentiment but is unlikely to drive a sustained repricing without additional fundamental catalysts.

03

What to watch

The article doesn’t state whether there were concurrent buys, option exercises, or other insider activity; traders should check subsequent Form 4s for pattern changes.

Relevance 2/10Novelty 5/10Timing: Filed 2026-06-17; sale executed 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

$PHVSNeutralHigh confidence
Context

CEO Modig Berndt sold 2,291 PHVS shares in an open-market transaction on 2026-06-15 under a 10b5-1 plan, totaling $71,173.

Expected impact

Low near-term impact; any reaction likely fades unless follow-on selling accelerates or is paired with other negative news.

Evidence & confidence

The filing is a Form 4 insider sale with stated 10b5-1 pre-arranged plan and modest dollar value versus typical market moves, implying informational content is limited.

Market effects

No sector-level read-through; this is company-specific insider transaction disclosure.

Minimal—no cross-market catalyst described.

Minimal—no international deal/regulatory/clinical catalyst mentioned.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still reflect management’s view of near-term risk or liquidity needs; monitor for clustering of sales.

Key entities

  • Pharvaris N.V.

    Subject of the Form 4 insider sale disclosure.

  • Modig Berndt

    CEO and director who sold PHVS shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.